Curriculum Vitaes
Profile Information
- Affiliation
- School of Medicine, Fujita Health University
- Degree
- 博士(医学)(名古屋大学)
- J-GLOBAL ID
- 200901048638344557
- researchmap Member ID
- 5000024641
- External link
Education:
1993 Ph.D. (Dr of Medical Science) Nagoya University The Graduate School of Medicine
(Prof. Toshiharu Nagatsu)
1989 M.D. Nagoya University School of Medicine
Professional training:
2017-present Vice president, Fujita Health University
2015-present Dean of the School of Medicine, Fujita Health University
2003-present Professor, Dep. Psychiatry, Fujita Health University School of Medicine
2002-2003 Assoc. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
1998-2002 Assit. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
(Prof. Norio Ozaki)
1996-1998 Visiting Fellow, Lab. Neurogenetics, NIAAA/NIH
(Dr. David Goldman)
1994-1996 Medical Staff, Dep. Psychiatry, Nagoya University School of Medicine
(Prof. Tatsuro Ohta)
1993-1994 Clinical Fellow in Medicine, North Hospital, Nagoya
1989-1990 Resident in Medicine, Kyoritsu General Hospital, Nagoya
Research field
Psychiatric genetics, Pharmacogenetics, Clinical psychopharmacology
NAKAO IWATA, M.D., Ph.D. is Professor of Psychiatry Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, JAPAN. He attended medical school and graduate school at Nagoya University and majored molecular neurochemistry and clinical psychiatry. He has published on many topics, including psychiatric genetics, pharmacogenomics, and clinical neuropsychopharmacology.
1993 Ph.D. (Dr of Medical Science) Nagoya University The Graduate School of Medicine
(Prof. Toshiharu Nagatsu)
1989 M.D. Nagoya University School of Medicine
Professional training:
2017-present Vice president, Fujita Health University
2015-present Dean of the School of Medicine, Fujita Health University
2003-present Professor, Dep. Psychiatry, Fujita Health University School of Medicine
2002-2003 Assoc. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
1998-2002 Assit. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
(Prof. Norio Ozaki)
1996-1998 Visiting Fellow, Lab. Neurogenetics, NIAAA/NIH
(Dr. David Goldman)
1994-1996 Medical Staff, Dep. Psychiatry, Nagoya University School of Medicine
(Prof. Tatsuro Ohta)
1993-1994 Clinical Fellow in Medicine, North Hospital, Nagoya
1989-1990 Resident in Medicine, Kyoritsu General Hospital, Nagoya
Research field
Psychiatric genetics, Pharmacogenetics, Clinical psychopharmacology
NAKAO IWATA, M.D., Ph.D. is Professor of Psychiatry Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, JAPAN. He attended medical school and graduate school at Nagoya University and majored molecular neurochemistry and clinical psychiatry. He has published on many topics, including psychiatric genetics, pharmacogenomics, and clinical neuropsychopharmacology.
Research Areas
1Research History
5Education
2-
1983 - 1989
Papers
659-
Psychiatry and clinical neurosciences, Feb 10, 2026AIM: This network meta-analysis of randomized controlled trials (RCTs) aimed to investigate which hypnotics are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea. METHODS: Primary outcomes included total sleep time (TST) and apnea-hypopnea index (AHI) during TST. Other outcomes were rapid eye movement (REM) sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI during non-REM or REM sleep, mean peripheral oxygen saturation (SpO2) during TST, mean SpO2 nadir during TST, arousal index (AI), all-cause discontinuation, adverse event-related discontinuation, and incidence of individual adverse events. Effect sizes with 95% confidence intervals were calculated. RESULTS: This systematic review included 32 RCTs (n = 1871, average age = 51.60 years, 62.52% male, mean AHI = 23.60). Our network meta-analysis evaluated brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Compared with placebo, lemborexant increased TST, REM sleep time, and SE and decreased LPS and WASO, whereas both daridorexant and zolpidem increased TST and SE and decreased WASO. These three medications demonstrated respiratory safety and discontinuation profiles similar to those of placebo. Eszopiclone increased TST and SE and decreased LPS, WASO, AHI during TST, and AI, but its effects on LPS, WASO, AHI during TST, and AI disappeared in the sensitivity analysis, excluding continuous positive airway pressure titration studies. CONCLUSION: Our network meta-analysis identified different effects of various hypnotics on sleep architecture and respiratory parameters; however, the lack of data prevented a formal synthesis of subjective outcomes. Therefore, these results should be interpreted with caution in clinical practice.
-
Schizophrenia research. Cognition, 42 100390-100390, Dec, 2025BACKGROUND: Cognitive dysfunction has a significant impact on social functioning, such as employment, in patients with schizophrenia. However, existing cognitive assessments are time-consuming, impose a significant burden on patients, and require specialized training for evaluators, making them impractical for routine clinical use. Therefore, the present study investigated whether a simple and novel assessment tool, called Psychomotor Function Tests (PFT), correlates with existing Neuropsychological Tests (NT) and assessments with the Life Assessment Scale for the Mentally Ill (LASMI), which evaluates social functioning, including employment. METHODS: Cognitive function was examined in 24 patients with schizophrenia using NT (the Japanese Adult Reading Test, Trail Making Test (TMT), and word fluency test) and tablet-based PFT, while social functioning was evaluated using LASMI. Twenty-four healthy controls (HCs) underwent the same cognitive assessments. RESULTS: Psychomotor function, as evaluated by the choice reaction time, compensatory tracking test, and rapid visual information processing, was significantly worse in patients with schizophrenia than in HCs (p < 0.001). Furthermore, the composite score of PFT correlated with the time required for TMT (r = -0.707, -0.637) and LASMI subscales related to work, endurance & stability, self-recognition, required skills, and retention skills (r = -0.640, -0.689, -0.634, -0.420, -0.548). CONCLUSION: PFT correlated with existing NT, which are widely used in cognitive function assessments. Cognitive function examined by PFT was closely associated with social functioning. These results suggest the potential of PFT for evaluating cognitive function in routine clinical settings for patients with schizophrenia.
-
Molecular psychiatry, Nov 5, 2025Sensory issues are common in autism spectrum disorders (ASD) and can significantly affect daily living. The phenomena of gating and habituation of event-related potentials (ERPs) to repetitive stimuli have been suggested as potential biomarkers reflecting atypical sensory processing in ASD. Sensory hypersensitivity and anxiety are closely related in ASD, and habituation to emotionally evocative stimuli may serve as a more sensitive biomarker for sensory hypersensitivity symptoms. However, previous studies have primarily used tonal stimuli, and there has been little investigation into whether habituation to emotionally evocative sounds is impaired in ASD patients. In this study, we compared the degree of habituation of the P1-N1 peak-to-peak amplitude in response to repeated tones and fearful vocalizations between control and ASD groups. Contrary to expectations, no significant difference was observed for fearful vocalizations between the groups, while ASD patients showed significantly reduced habituation to tonal sounds in the left parieto-occipital region. Furthermore, we found a significant correlation between the degree of habituation to tonal sounds in the left parieto-occipital region and sensory hypersensitivity symptoms in ASD patients, and similar abnormalities in BTBR mice, an animal model of ASD. These results suggest that habituation to tonal sounds, rather than emotionally evocative stimuli, may serve as a translational biomarker reflecting sensory hypersensitivity symptoms.
-
Neuropsychopharmacology Reports, 45(3), Sep 4, 2025ABSTRACT Objective To examine the characteristics associated with happiness in Japanese individuals with schizophrenia. Methods A self‐reported online survey was conducted in 2022 among individuals aged 20–75 years, including 223 and 1776 individuals with and without schizophrenia, respectively. We used a modified Poisson regression to assess the factors associated with happiness by calculating the age‐ and sex‐adjusted prevalence ratios (PRs). We examined within‐schizophrenia group differences by age and sex strata, and compared these stratified PRs between groups with and without schizophrenia. Results Among participants with schizophrenia, happiness was significantly associated with self‐rated health status (PR = 1.75), Ikigai (PR = 5.02), depressive symptoms (PR = 0.43), perceived stress (PR = 0.52), cognitive social capital (PR = 2.07), structural social capital (PR = 1.70), social support (PR = 2.40), close friends (PR = 1.88), close relatives (PR = 2.34), and a cohabiting partner (PR = 1.57). Within the schizophrenia group, sex differences were significant for cognitive social capital (men: PR = 3.45; women: PR = 1.43) and cohabiting partners (men: PR = 2.26; women: PR = 1.25), whereas no significant age differences were found. Factors demonstrating a stronger association in participants with schizophrenia than in those without schizophrenia included: Ikigai (with, PR = 5.02; without, PR = 2.91), cognitive social capital (with, PR = 2.07; without, PR = 1.49), and structural social capital (with, PR = 1.70; without, PR = 1.24). Conclusion Happiness in individuals with schizophrenia is associated with physical, mental, and social factors, with social factors exhibiting sex‐related differences.
Misc.
650-
精神神経学雑誌, (2013特別) S-545, May, 2013
-
Sleep and Biological Rhythms, 11(2) 65-73, 2013 Peer-reviewed
-
VALUE IN HEALTH, 15(7) A342-A342, Nov, 2012
-
日本医療薬学会年会講演要旨集, 22 452-452, Oct 10, 2012
-
不眠研究, 2012 128-130, Oct, 201270代男。受診の2ヵ月ほど前から不眠と夜間入眠後の異常行動(下着を脱いで放尿する、歩いて柱に頭をぶつけるなど)が出現した。不眠を主訴に受診し、レム睡眠行動障害あるいは他のパラソムニアを疑った。連日の夜間異常行動により家族が疲弊していたためクロナゼパムを投与したが、ほぼ無効であり、精査目的で入院となった。PSG所見から無呼吸イベントをトリガーとして覚醒脳波下に異常行動を反復することが確認され、睡眠時無呼吸症候群(SAS)によるパラソムニアと診断した。治療はSASを抑えることで異常行動の抑制を図る方針とし、側臥位を励行するとともに、CPAPタイトレーションを行い、圧10cmにて無呼吸は消失した。
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 22回・42回 143-143, Oct, 2012
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 22回・42回 168-168, Oct, 2012
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 22回・42回 174-174, Oct, 2012
-
日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 22回・42回 193-193, Oct, 2012
-
日本睡眠学会定期学術集会プログラム・抄録集, 37回 272-272, Jun, 2012
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 15 199-199, Jun, 2012
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 15 233-233, Jun, 2012
-
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 15 140-140, Jun, 2012
-
精神神経学雑誌, (2012特別) S-232, May, 2012
-
精神神経学雑誌, (2012特別) S-302, May, 2012
-
BIOLOGICAL PSYCHIATRY, 71(8) 120S-121S, Apr, 2012
-
SCHIZOPHRENIA RESEARCH, 136 S318-S318, Apr, 2012
-
Pharma Medica, 30(3) 197-199, Mar, 2012drugナイーブな急性期統合失調症患者8例(男性5例、女性3例、平均年齢37.3歳)を対象に、8週間のオープンラベル試験にてブロナンセリンの有効性と安全性を検討した。その結果、1)8週の試験を継続できたのは4例であった。残り4例中1例は症状改善で転院希望により、他の1例は効果不十分、2例は副作用により脱落となった。2)治療反応率は2週目4/8例、4週目3/5例で、8週目は継続できた4例とも改善しているため4/4例であった。だが、エンドポイントは6/8例であった。3)PANSS-ECスコアでは1週目ですでに改善がみられ、サブスコールスコアでは特に陽性症状で強い改善傾向が示された。CGIも2週目時点で改善が得られ、試験開始時点では半数以上が「重度異常」であったのに対し、エンドポイントでは半数以上が「軽度異常」となった。4)副作用は椎体外路症状が3例にみられ、1例は抗パーキンソン病薬併用にて軽減・完遂したものの、2例は抗パーキンソン薬併用にても改善せず、試験の中止となった。
-
日本薬学会年会要旨集, 132年会(4) 336-336, Mar, 2012
Books and Other Publications
6Research Projects
16-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2016 - Mar, 2019
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2013 - Mar, 2016
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, 2010 - 2012




